Cargando…
Targeting CD56 with an antibody–drug conjugate in Merkel cell carcinoma
Linked Article: Esnault et al. Br J Dermatol 2022; 186:295–306.
Autores principales: | Leiendecker, L., Jung, P.S., Obenauf, A.C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298988/ https://www.ncbi.nlm.nih.gov/pubmed/34817859 http://dx.doi.org/10.1111/bjd.20894 |
Ejemplares similares
-
LSD1 inhibition induces differentiation and cell death in Merkel cell carcinoma
por: Leiendecker, Lukas, et al.
Publicado: (2020) -
Merkel cell polyomavirus and cutaneous Merkel cell carcinoma
por: Minutilli, Ettore, et al.
Publicado: (2016) -
Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors
por: Shah, Manisha H., et al.
Publicado: (2016) -
Association of Merkel Cell Polyomavirus–Specific Antibodies With Merkel Cell Carcinoma
por: Carter, Joseph J., et al.
Publicado: (2009) -
Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models
por: Yu, Lin, et al.
Publicado: (2017)